Cuprina Holdings (Cayman) Limited — Form 6-K Summary
Reporting period: September 2026. The filing reports a capital-markets transaction, not operating or interim financial results.
Business context and transaction
On September 29, 2026, the company completed the underwriters’ full exercise of their 45-day over-allotment option in connection with its public offering, which was initially completed on September 17, 2026.
Key financial and offering metrics
- The company issued and sold 648,373 Class A ordinary shares at $1.15 per share, generating approximately $745,629 in additional gross proceeds.
- Including the over-allotment shares, the offering comprised 4,970,862 shares and raised approximately $5,716,491 in aggregate gross proceeds, before underwriting discounts, commissions, and estimated offering expenses.
- The filing provides no revenue, profit, cash flow, margin, debt, or liquidity figures.
Material changes and potential dilution
The over-allotment exercise increased the shares issued in the offering beyond the initial 4,322,489 shares. The company also issued the underwriters’ representative warrants to purchase up to 25,935 Class A ordinary shares at an initial exercise price of $1.265 per share. The warrants are exercisable during a four-and-one-half-year period beginning six months after sales of the offering commenced and include registration rights and customary anti-dilution provisions.
Outlook, risks, and unusual items
The filing provides no business guidance or operating outlook. Gross proceeds are stated before offering costs; net proceeds are not specified. The additional shares and warrants may dilute existing shareholders. The filing also notes that the securities are not offered for sale where doing so would be unlawful before applicable registration or qualification.
Important facts for investors to verify
- Net proceeds after underwriting discounts, commissions, and offering expenses.
- The shares outstanding after the offering and the potential impact of warrant exercise.
- The warrant terms, including exercisability dates, registration rights, and anti-dilution provisions.